Genmab A/S · OMXCOP:GMAB
Genmab A/S — 9M 2009 Earnings Presentation
6 slides from Genmab A/S's earnings presentation, November 2009
Slide 1: Interim Report
Interim Report 9 months ending Sep 30, 2009
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Key Data
Key Data 9 Months ended September 30, 2009 2009 2008 2009 2008 DKK millions USD millions * Revenue 435 667 86 131 Net Loss (403) (526) (79) (104) Manufacturing employees 158 175 All other employees 362 468 Employees at end of period 520 643 DKK millions USD millions * Cash and marketable securities
Slide 4: Income Statement
Income Statement 9 Months ended September 30, 2009 2009 2008 2009 2008 DKK millions USD millions * Revenue 435 667 86 131 Cost of Sales (38) (44) (7) (9) R&D Costs (818) (1,021) (161) (201) G&A Expenses (115) (110) (23) (21) Operating Expenses (971) (1,175) (191) (231) Operating Loss (536) (508) (10
Slide 5: Guidance
Guidance 2009 2009 Guidance New Previous With Before Before Reorganization Reorganization Reorganization DKK USD DKK USD DKK USD Millions Millions Millions Millions Millions Millions Revenues 640 126 640 126 750 148 Operating expenses 1,300 256 1,300 256 1,400 275 Reorganization charge 80 15 - - - -
Slide 6: Highlights & Subsequent Events
Highlights & Subsequent Events FDA approval of Arzerra™ (ofatumumab) in CLL refractory to fludarabine & alemtuzumab Ofatumumab Top-line results reported in four studies Completed recruitment in Phase III CLL and Phase II DLBCL studies Initiated Phase III study in relapsed or refractory DLBCL vs. rit